AMAG AMAG Pharmaceuticals Inc.

11.49
-0.35  -3%
Previous Close 11.84
Open 11.71
Price To Book 0.81
Market Cap 389,692,151
Shares 33,915,766
Volume 1,331,668
Short Ratio
Av. Daily Volume 743,239
Stock charts supplied by TradingView

NewsSee all news

  1. AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update

    Initiating CEO transition plan Divesting Intrarosa® and Vyleesi®  2020 financial guidance reflects reduction in annual operating expenses of more than $100M and a return to positive adjusted EBITDA WALTHAM, Mass.,

  2. AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020

  3. AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research

    WALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- As part of the company's ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

  4. AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

    WALTHAM, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Jefferies 2019 London

  5. AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Commercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available for at-risk pregnant

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 top-line data due 1H 2020.
AMAG-423 / Digoxin immune fab (DIF)
Severe preeclampsia in pregnant women
FDA approval announced June 21, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Approval for sNDA filing announced February 5, 2018.
Feraheme
Adults with iron deficiency anemia (IDA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.
Makena
Preterm birth
End of Phase 2 trial meeting slated for 2H 2020.
Ciraparantag
Anticoagulated reversal agent / Healthy volunteers

Latest News

  1. AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update

    Initiating CEO transition plan Divesting Intrarosa® and Vyleesi®  2020 financial guidance reflects reduction in annual operating expenses of more than $100M and a return to positive adjusted EBITDA WALTHAM, Mass.,

  2. AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020

  3. AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research

    WALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- As part of the company's ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

  4. AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

    WALTHAM, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Jefferies 2019 London

  5. AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Commercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available for at-risk pregnant

  6. AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)

    WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced  the U.S. Food and Drug Administration's (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to

  7. AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial

    WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration (FDA) Bone,

  8. AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology

    WALTHAM, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin's Role in Optimizing Neonatal Gestation) were published online in the

  9. AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

    WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG") today announced that it has entered into a settlement agreement with Caligan Partners LP ("Caligan"). As part of this

  10. Caligan Partners Issues Letter to AMAG Shareholders

    AMAG's Recent Public Letter Demonstrates Complete Disregard for Shareholders Current Board's Poor Decisions, Strategic Missteps and Lax Oversight Have Destroyed $1.1 Billion in Shareholder Value over Past Seven Years

  11. AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, October 3, 2019. Ted Myles,

  12. AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders

    Details Caligan Partners' Reckless Business Ideas and Inexperienced Director Nominees Urges Shareholders to Sign and Return AMAG's GREEN Consent Revocation Card WALTHAM, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- AMAG

  13. Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders

    Believes Removal of Four Incumbent Directors is Necessary to Stop Value Destruction at AMAG Caligan's Four Highly-Qualified Nominees Have the Experience and Skillsets Needed to Conduct Comprehensive Review of

  14. AMAG Sends Letter to Shareholders

    WALTHAM, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG" or the "Company") today issued the following letter, which will be mailed to its shareholders. AMAG's Board urges all

  15. AMAG Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019. Bill Heiden, president and

  16. AMAG Urges Stockholders to Take No Action on Caligan Partners' Consent Solicitation Materials

    WALTHAM, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG" or the "Company") today responded to the preliminary consent solicitation filed by Caligan Partners ("Caligan") with

  17. AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection)

    The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients WALTHAM, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- AMAG